Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.48 |
| ▸ | CA1 | P00915 | 16/20 | 0.48 |
| ▸ | CA9 | Q16790 | 10/20 | 0.38 |
| ▸ | CA12 | O43570 | 7/20 | 0.37 |
| ▸ | CA7 | P43166 | 6/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA6 | P23280 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708336 | 0.86 | CA2 (0.52) | CA2CA1CA9CA12CA7 | |
| SCHEMBL21708223 | 0.86 | CA2 (0.44) | CA2CA1CA9CA12CA7 | |
| SCHEMBL6277726 | 0.83 | CA2 (0.39) | CA2CA1CA9CA12CA7 | |
| SCHEMBL6285121 | 0.83 | CA2 (0.39) | CA2CA1CA9CA12CA7 | |
| SCHEMBL6171423 | 0.82 | — | — | |
| SCHEMBL4359971 | 0.79 | CA2 (0.40) | CA2CA1CA9CA12CA7 | |
| SCHEMBL6222747 | 0.78 | CA2 (0.59) | CA2CA1CA9CA7CA5A | |
| SCHEMBL6277563 | 0.78 | CA2 (0.59) | CA2CA1CA9CA7CA5A | |
| SCHEMBL6277779 | 0.78 | CA2 (0.59) | CA2CA1CA9CA7CA5A | |
| SCHEMBL13251209 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| EP-3611175-B1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | YAMAMOTO CHEMICALS INC (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-11174274-B2 | Naphthalocyanine compound, method for producing same, and use thereof | YAMAMOTO CHEMICALS, INC. (JP) | 2021-11-16 | — | — | US | disclosed |
| US-20210107924-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | YAMAMOTO CHEMICALS, INC. (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611175-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | Yamamoto Chemicals, Inc. (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107924-A1 | NAPHTHALOCYANINE COMPOUND, METHOD FOR PRODUCING SAME, AND USE THEREOF | MRPS9, INTS9, RPL19 | CA2 1085/4885CA1 734/4885CA9 59/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | CA2 4422/4885CA1 4798/4885CA9 4211/4885 |
| US-11174274-B2 | Naphthalocyanine compound, method for producing same, and use thereof | MRPS9, INTS9, RPL19 | CA2 1085/4885CA1 734/4885CA9 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.